739 related articles for article (PubMed ID: 27083005)
1. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).
Zak KM; Grudnik P; Guzik K; Zieba BJ; Musielak B; Dömling A; Dubin G; Holak TA
Oncotarget; 2016 May; 7(21):30323-35. PubMed ID: 27083005
[TBL] [Abstract][Full Text] [Related]
2. Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1.
Guzik K; Zak KM; Grudnik P; Magiera K; Musielak B; Törner R; Skalniak L; Dömling A; Dubin G; Holak TA
J Med Chem; 2017 Jul; 60(13):5857-5867. PubMed ID: 28613862
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy.
Zhang H; Xia Y; Yu C; Du H; Liu J; Li H; Huang S; Zhu Q; Xu Y; Zou Y
Molecules; 2021 Jun; 26(11):. PubMed ID: 34199417
[TBL] [Abstract][Full Text] [Related]
4. Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.
Zak KM; Kitel R; Przetocka S; Golik P; Guzik K; Musielak B; Dömling A; Dubin G; Holak TA
Structure; 2015 Dec; 23(12):2341-2348. PubMed ID: 26602187
[TBL] [Abstract][Full Text] [Related]
5. Investigation of protein-protein interactions and hot spot region between PD-1 and PD-L1 by fragment molecular orbital method.
Lim H; Chun J; Jin X; Kim J; Yoon J; No KT
Sci Rep; 2019 Nov; 9(1):16727. PubMed ID: 31723178
[TBL] [Abstract][Full Text] [Related]
6. Fragment-based screening of programmed death ligand 1 (PD-L1).
Perry E; Mills JJ; Zhao B; Wang F; Sun Q; Christov PP; Tarr JC; Rietz TA; Olejniczak ET; Lee T; Fesik S
Bioorg Med Chem Lett; 2019 Mar; 29(6):786-790. PubMed ID: 30728114
[TBL] [Abstract][Full Text] [Related]
7. Symmetry-based ligand design and evaluation of small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 interaction.
Kawashita S; Aoyagi K; Yamanaka H; Hantani R; Naruoka S; Tanimoto A; Hori Y; Toyonaga Y; Fukushima K; Miyazaki S; Hantani Y
Bioorg Med Chem Lett; 2019 Sep; 29(17):2464-2467. PubMed ID: 31351692
[TBL] [Abstract][Full Text] [Related]
8. Insights into non-peptide small-molecule inhibitors of the PD-1/PD-L1 interaction: Development and perspective.
Wu X; Meng Y; Liu L; Gong G; Zhang H; Hou Y; Liu C; Wu D; Qin M
Bioorg Med Chem; 2021 Mar; 33():116038. PubMed ID: 33517226
[TBL] [Abstract][Full Text] [Related]
9. Discovery of phenyl-linked symmetric small molecules as inhibitors of the programmed cell death-1/programmed cell death-ligand 1 interaction.
Wu Y; Zhang Y; Guo Y; Pan Z; Zhong S; Jin X; Zhuang W; Chen S; Gao J; Huang W; Dong X; Che J
Eur J Med Chem; 2021 Nov; 223():113637. PubMed ID: 34147746
[TBL] [Abstract][Full Text] [Related]
10. Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules.
Lin X; Lu X; Luo G; Xiang H
Eur J Med Chem; 2020 Jan; 186():111876. PubMed ID: 31761384
[TBL] [Abstract][Full Text] [Related]
11. Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2.
Zak KM; Grudnik P; Magiera K; Dömling A; Dubin G; Holak TA
Structure; 2017 Aug; 25(8):1163-1174. PubMed ID: 28768162
[TBL] [Abstract][Full Text] [Related]
12. Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation.
Pan C; Yang H; Lu Y; Hu S; Wu Y; He Q; Dong X
Eur J Med Chem; 2021 Mar; 213():113170. PubMed ID: 33454550
[TBL] [Abstract][Full Text] [Related]
13. Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways.
Sasikumar PG; Ramachandra M
BioDrugs; 2018 Oct; 32(5):481-497. PubMed ID: 30168070
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules.
Yang J; Hu L
Med Res Rev; 2019 Jan; 39(1):265-301. PubMed ID: 30215856
[TBL] [Abstract][Full Text] [Related]
15. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive in vitro characterization of PD-L1 small molecule inhibitors.
Ganesan A; Ahmed M; Okoye I; Arutyunova E; Babu D; Turnbull WL; Kundu JK; Shields J; Agopsowicz KC; Xu L; Tabana Y; Srivastava N; Zhang G; Moon TC; Belovodskiy A; Hena M; Kandadai AS; Hosseini SN; Hitt M; Walker J; Smylie M; West FG; Siraki AG; Lemieux MJ; Elahi S; Nieman JA; Tyrrell DL; Houghton M; Barakat K
Sci Rep; 2019 Aug; 9(1):12392. PubMed ID: 31455818
[TBL] [Abstract][Full Text] [Related]
17. PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules.
Geng Q; Jiao P; Jin P; Su G; Dong J; Yan B
Curr Pharm Des; 2018 Feb; 23(39):6033-6041. PubMed ID: 28982322
[TBL] [Abstract][Full Text] [Related]
18. From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway.
Zhan MM; Hu XQ; Liu XX; Ruan BF; Xu J; Liao C
Drug Discov Today; 2016 Jun; 21(6):1027-36. PubMed ID: 27094104
[TBL] [Abstract][Full Text] [Related]
19. Discovery of quinazoline derivatives as novel small-molecule inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction.
Wang Y; Kun Huang ; Gao Y; Yuan D; Ling L; Liu J; Wu S; Chen R; Li H; Xiong Y; Liu H; Ma J
Eur J Med Chem; 2022 Feb; 229():113998. PubMed ID: 34839997
[TBL] [Abstract][Full Text] [Related]
20. Protein Footprinting and X-ray Crystallography Reveal the Interaction of PD-L1 and a Macrocyclic Peptide.
Niu B; Appleby TC; Wang R; Morar M; Voight J; Villaseñor AG; Clancy S; Wise S; Belzile JP; Papalia G; Wong M; Brendza KM; Lad L; Gross ML
Biochemistry; 2020 Feb; 59(4):541-551. PubMed ID: 31841311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]